Thus, the hyperactive eCB system has led to the targeting through antagonism or inverse agonism of CB1 recep- tors for the development not only of anti-obesity/T2D [17], but also of anti-nicotine and -alcohol addiction drugs [18]. Additionally, CB1 blockers have been benefi- cial for ...